Skip to main content
SpringerLink
Log in

Pretreatment F-18 FDG PET/CT Parameters to Evaluate Progression-Free Survival in Gastric Cancer

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

We performed this study to evaluate the predictive value of pretreatment F-18 FDG PET/CT for progression-free survival (PFS) in patients with gastric cancer.

Methods

Of 321 patients with a diagnosis of gastric cancer, we retrospectively enrolled 97 patients (men:women = 61:36, age 59.8 ± 13.2 years), who underwent pretreatment F-18 fluoro-2-deoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) from January 2009 to December 2009. Maximum standardized uptake value (SUVmax) was measured for each case with detectable primary lesions. In the remaining non-detectable cases, SUVmax was measured from the corresponding site seen on gastroduodenoscopy for analysis. In subgroup analysis, metabolic tumor volume (MTV) was measured in 50 patients with clearly distinguishable primary lesions. SUVmax, stage, depth of tumor invasion and presence of lymph node metastasis were analyzed in terms of PFS. Receiver operating characteristic (ROC) curves were used to find optimal cutoff values of SUVmax and MTV for disease progression. The relationship between SUVmax, MTV and PFS was analyzed using the Kaplan-Meier with log-rank test and Cox’s proportional hazard regression methods.

Results

Of 97 patients, 15 (15.5 %) had disease progression. The mean follow-up duration was 29.6 ± 10.2 months. The mean PFS of low SUVmax group (≤5.74) was significantly longer than that of the high SUVmax group (>5.74) (30.9 ± 8.0 vs 24.3 ± 13.6 months, p = 0.008). In univariate analysis, stage (I vs II, III, IV), depth of tumor invasion (T1 vs T2, T3, T4), presence of lymph node metastasis and SUVmax (>5.74 vs ≤5.74) were significantly associated with recurrence. In multivariate analysis, high SUVmax (>5.74) was the only poor prognostic factor for PFS (p = 0.002, HR 11.03, 95 % CI 2.48–49.05). Subgroup multivariate analysis revealed that high MTV (>16.42) was the only poor prognostic factor for PFS (p = 0.034, HR 3.59, 95 % CI 1.10–11.71).

Conclusion

In gastric cancer, SUVmax measured by pretreatment F-18 FDG PET/CT has a significant predictive value for PFS. In addition, if MTV is measurable, high MTV is an independent factor for disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward D, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:60–90.

    Article  Google Scholar 

  2. Shin A, Kim J, Park S. Gastric cancer epidemiology in Korea. J Gastric Cancer. 2011;11:135–40.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;14:31–6.

    Google Scholar 

  4. Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer. 2000;89:255–61.

    Article  CAS  PubMed  Google Scholar 

  5. Wang X, Wan F, Pan J, Yu GZ, Chen Y, Wang JJ. Tumor size: a non-neglectable independent prognostic factor for gastric cancer. J Surg Oncol. 2008;97:236–40.

    Article  PubMed  Google Scholar 

  6. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136–43.

    Article  CAS  PubMed  Google Scholar 

  7. Davies A, Tan C, Paschalides C, Barrington SF, O’Doherty M, Utley M, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer. 2007;55:75–8.

    Article  PubMed  Google Scholar 

  8. Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907–11.

    CAS  PubMed  Google Scholar 

  9. Konski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G, et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1123–8.

    Article  PubMed  Google Scholar 

  10. Greco C, Rosenzweig K, Cascini GL, Tamburrini O. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer. 2007;57:125–34.

    Article  PubMed  Google Scholar 

  11. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, el El-Ghazi A, Lehmann W, et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–404.

    Article  CAS  PubMed  Google Scholar 

  12. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120:270–4.

    Article  PubMed  Google Scholar 

  13. Yoo SW, Kim JH, Chong A, Kwon SY, Min JJ, Song HC, et al. Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging. 2012;46:286–93.

    Article  CAS  Google Scholar 

  14. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861–8.

    Article  CAS  PubMed  Google Scholar 

  15. Choi KH, Yoo IR, Han EJ, Kim YS, Kim GW, Na SJ, et al. Prognostic value of metabolic tumor volume measured by F-18 FDG PET/CT in locally advanced head and neck squamous cell carcinomas treated by surgery. Nucl Med Mol Imaging. 2011;45:43–51.

    Article  Google Scholar 

  16. Kim JH, Yoo SW, Kang SR, Cho SG, Oh JR, Min JJ, et al. Prognostic significance of metabolic tumor volume measured by F-18 FDG PET/CT in operable primary breast cancer. Nucl Med Mol Imaging. 2012;46:278–85.

    Article  Google Scholar 

  17. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17:115–22.

    Article  PubMed  Google Scholar 

  18. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging. 2002;29:525–9.

    Article  PubMed  Google Scholar 

  19. Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol. 2009;35:449–55.

    Article  CAS  PubMed  Google Scholar 

  20. Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, et al. Lymph node staging of gastric cancer using 18F-FDG PET: a comparison study with CT. J Nucl Med. 2005;46:1582–8.

    PubMed  Google Scholar 

  21. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.

    Article  PubMed  Google Scholar 

  22. Mochiki E, Kuwano H, Katoh H, Asao T, Oriuchi N, Endo K. Evaluation of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg. 2004;28:247–53.

    Article  PubMed  Google Scholar 

  23. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging. 2006;33:148–55.

    Article  PubMed  Google Scholar 

  24. Oh HH, Lee SE, Choi IS, Choi WJ, Yoon DS, Min HS, et al. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer. J Surg Oncol. 2011;104:530–3.

    Article  PubMed  Google Scholar 

  25. Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9:192–6.

    Article  PubMed  Google Scholar 

  26. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30:288–95.

    Article  CAS  PubMed  Google Scholar 

  27. Koga H, Sasaki M, Kuwabara Y, Hiraka K, Nakagawa M, Abe K, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med. 2003;17:733–8.

    Article  CAS  PubMed  Google Scholar 

  28. Takahashi H, Ukawa K, Ohkawa N, Kato K, Hayashi Y, Yoshimoto K, et al. Significance of 18F-2-deoxy-2-fluoro-glucose accumulation in the stomach on positron emission tomography. Ann Nucl Med. 2009;23:391–7.

    Article  PubMed  Google Scholar 

  29. Hur H, Kim SH, Kim W, Song KY, Park CH, Jeon HM. The efficacy of preoperative PET/CT for prediction of curability in surgery for locally advanced gastric carcinoma. World J Surg Oncol. 2010;8:86.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Chung HW, Lee EJ, Cho Y, Yoon SY, So Y, Kim S, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol. 2010;136:1929–35.

    Article  PubMed  Google Scholar 

  31. Park JC, Lee JH, Cheoi K, Chung H, Yun MJ, Lee H, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging. 2012;39:1107–16.

    Article  CAS  PubMed  Google Scholar 

  32. Lee JW, Lee SM, Lee MS, Shin HC. Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. Eur J Nucl Med Mol Imaging. 2012;39:1425–34.

    Article  PubMed  Google Scholar 

  33. Kamimura K, Nagamachi S, Wakamatsu H, Fujita S, Nishii R, Umemura Y, et al. Role of gastric distension with additional water in differentiating locally advanced gastric carcinomas from physiologic uptake in the stomach on 18F-fluoro-2-deoxy-D-glucose PET. Nucl Med Commun. 2009;30:431–9.

    Article  PubMed  Google Scholar 

  34. Yun M, Choi HS, Yoo E, Bong JK, Ryu YH, Lee JD. The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. J Nucl Med. 2005;46:953–7.

    PubMed  Google Scholar 

Download references

Conflict of Interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Republic of Korea

    Jeonghun Kim, Seok Tae Lim, Chang Ju Na, Yeon-Hee Han, Hwan-Jeong Jeong & Myung-Hee Sohn

  2. Department of Surgery, Research Institute of Clinical Medicine, Chonbuk National University Medical School and Hospital, Jeonju, Republic of Korea

    Chan-Young Kim

  3. Department of Nuclear Medicine, Research Institute of Clinical Medicine, Cyclotron Research Center, Molecular Imaging & Therapeutic Medicine Research Center, Chonbuk National University Medical School and Hospital, Jeonju, Republic of Korea

    Seok Tae Lim, Hwan-Jeong Jeong & Myung-Hee Sohn

Authors
  1. Jeonghun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seok Tae Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang Ju Na
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yeon-Hee Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chan-Young Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hwan-Jeong Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Myung-Hee Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seok Tae Lim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J., Lim, S.T., Na, C.J. et al. Pretreatment F-18 FDG PET/CT Parameters to Evaluate Progression-Free Survival in Gastric Cancer. Nucl Med Mol Imaging 48, 33–40 (2014). https://doi.org/10.1007/s13139-013-0243-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-013-0243-3

Keywords

Search

Navigation